Ampio's Ampion flunks another late-stage study; shares down 68% premarket

• Thinly traded micro cap Ampio Pharmaceuticals (NYSE:AMPE) craters 68% premarket on robust volume in response to its announcement that a Phase 3 clinical trial, PIVOT, assessing Ampion, an intra-articular injection for the potential treatment of pain associated with osteoarthritis (OA) of the knee, failed to beat placebo (saline injection).
• Ampion also failed a Phase 3 study in OA of the knee in 2015. The company says it will meet with the FDA to discuss all of its data.
• Management will host a conference call at 4:30 pm ET on Tuesday, July 5 to discuss the results.
• Ampion is a low molecular weight fraction of human serum albumin (HSA). Its main ingredient is an immunomodulatory molecule derived from HSA called aspartyl-alanyl diketopiperazine (DA-DKP). DA-DKP is believed to reduce inflammation by suppressing pro-inflammatory cytokine production in T cells.
• Previously: Ampio Pharma off 58% premarket on failed trial results (April 20, 2015)

Comments

[kimmitlanz]

Any chance AMPE back on track??